Drs. Desai and Abu Rous discuss trial data from Flaura2 and Mariposa as presented at 2024 ASCO, and the implications in treating EGFR+ NSCLC.
Drs. Desai and Abu Rous discuss the Crown study data as presented at ASCO 2024, and its implications in treating ALK+ NSCLC.
Drs. Desai and Abu Rous discuss the data, as presented at ASCO 2024, and how it may change the field of treatment for limited stage small Adriatic Studycell lung cancer.
Drs. Desai and Abu Rous discuss trial date from Mariposa2 and Laura as presented at 2024 ASCO, and the implications in treating EGFR+ NSCLC.
Drs. Desai and Abu Rous discuss using tarlatamab in treating extensive stage small cell lung cancer.
Drs. Patel, Sheth, and Weiss discuss emerging data and advances in thyroid cancer treatment.
Drs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in incurable HPV negative head and neck cancer.
Drs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in recurrent/metastatic HPV positive head and neck cancer.
Drs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in curable HPV negative head and neck cancer.
Drs. Patel, Sheth, and Weiss discuss current treatment options and emerging data in curable HPV positive head and neck cancer.
Dr. Marco Ruiz explains the concept of bone marrow transplant, and how it is used in treating blood cancers.
Drs. Goodman, Phillips, Taneja, and Rajeeve discuss whether a patient's location can affect the treatments they can access and their overall prognosis.
Drs. Goodman, Phillips, Taneja, and Rajeeve discuss how to navigate treatment and Covid vaccination.
Dr. Sridevi Rajeeve discusses current FDA approved bispecific antibodies and ones coming from clinical trials.
Dr. Alankrita Taneja examines data from the CESAR trial, and discusses curative strategies for Smoldering Multiple Myeloma.
Dr. Sridevi Rajeeve discusses possible side effects from bispecific antibodies, and how to manage them.
Dr. Sridevi Rajeeve discusses the unprecedented response rates in patients treated with teclistamab, talquetamab, and elranatamab, as well as their clinical trial data.
Dr. Tycel Phillips examines the efficacy of two medications against diffuse large b-cell lymphoma (DLBCL)
Dr. Aakash Desai discusses how to address the issues of cost and insurance approval when obtaining biomarker testing.
Dr. Aakash Desai emphasizes the importance of physicians ordering biomarker testing for patients with NSCLC